Troy Wilson - Kura Oncology Chairman
| KURA Stock | USD 17.99 0.60 3.23% |
Chairman
Dr. Troy E. Wilson, Ph.D., J.D., is the Chairman of the Board, President, Chief Executive Officer, Principal Accounting Officer of Kura Oncology, Inc. He has served as our President and Chief Executive Officer and as the chairman of our Board of Directors since the Merger in March 2015. Dr. Wilson cofounded Prior Kura in August 2014 and served as the President and Chief Executive Officer of Prior Kura, as well as a member of Prior Kuras Board of Directors, from August 2014 until the Upstream Merger in March 2015. Dr. Wilson served as President and Chief Executive Officer of Wellspring Biosciences, Inc., a privatelyheld biopharmaceutical company, and its parent company Araxes Pharma LLC from July 2012 to March 2019 and as President and Chief Executive Officer of Avidity Biosciences LLC, a privatelyheld biopharmaceutical company, from November 2012 to February 2019. Dr. Wilson served as the President and Chief Executive Officer and a member of the Board of Directors of Intellikine, Inc., a privatelyheld biopharmaceutical company, from April 2007 to January 2012 and from August 2007 to January 2012, respectively, until its acquisition by Takeda Pharmaceutical Company Limited. He has also been a member of the Board of Directors of Puma Biotechnology, Inc., a publiclyheld biopharmaceutical company, since October 2013, and a member of the Board of Directors of Zosano Pharma, Inc., a publiclyheld biopharmaceutical company, since June 2014 since 2018.
| Age | 49 |
| Tenure | 6 years |
| Address | 12730 High Bluff Drive, San Diego, CA, United States, 92130 |
| Phone | 858 500 8800 |
| Web | https://kuraoncology.com |
Troy Wilson Latest Insider Activity
Tracking and analyzing the buying and selling activities of Troy Wilson against Kura Oncology stock is an integral part of due diligence when investing in Kura Oncology. Troy Wilson insider activity provides valuable insight into whether Kura Oncology is net buyers or sellers over its current business cycle. Note, Kura Oncology insiders must abide by specific rules, including filing SEC forms every time they buy or sell Kura Oncology'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Troy Wilson over two months ago Exercise or conversion by Troy Wilson of 6945 shares of Kura Oncology subject to Rule 16b-3 | ||
Troy Wilson over three months ago Bona fide gift to Troy Wilson of 2000 shares of Kura Oncology subject to Section 16 | ||
Troy Wilson over six months ago Acquisition or disposition of Kura Oncology securities by Troy Wilson | ||
Troy Wilson over a year ago Acquisition or disposition of Kura Oncology securities by Troy Wilson |
Kura Oncology Management Efficiency
The company has return on total asset (ROA) of (0.229) % which means that it has lost $0.229 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3734) %, meaning that it created substantial loss on money invested by shareholders. Kura Oncology's management efficiency ratios could be used to measure how well Kura Oncology manages its routine affairs as well as how well it operates its assets and liabilities. As of April 18, 2024, Return On Tangible Assets is expected to decline to -0.36. The current year's Return On Capital Employed is expected to grow to -0.38. At present, Kura Oncology's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 454.1 M, whereas Return On Tangible Assets are forecasted to decline to (0.36).Similar Executives
| Found 2 records | CHAIRMAN Age | ||
| Luis Orozco | Betterware De Mexico | 71 | |
| Daniel Herndon | Home Federal Bancorp | 77 | |
Management Performance
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.23 |
Kura Oncology Leadership Team
Elected by the shareholders, the Kura Oncology's board of directors comprises two types of representatives: Kura Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kura. The board's role is to monitor Kura Oncology's management team and ensure that shareholders' interests are well served. Kura Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kura Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steven Stein, Director | ||
| Mollie MD, Executive Development | ||
| Francis Burrows, Senior Research | ||
| Roger Bakale, Clinical CMC | ||
| Thomas Malley, Director | ||
| Marc MD, Advisor | ||
| Mary Szela, Director | ||
| John Farnam, COO | ||
| Thomas Doyle, Principal Accounting | ||
| Esq JD, Chief Sec | ||
| MS MBA, Chief Officer | ||
| Kirsten Flowers, Chief Officer | ||
| Pingda Ren, Sr. VP of Chemistry and Pharmaceutical Sciences | ||
| Heidi Henson, CFO, Secretary | ||
| Troy Wilson, Chairman of the Board and Presidentident, CEO, Co-Founder | ||
| Kathleen Ford, Chief Officer | ||
| JD Esq, Chief Secretary | ||
| Stephen MD, Chief Officer | ||
| Faheem Hasnain, Independent Director | ||
| Annette North, Senior Vice President General Counsel | ||
| Liu Yi, Co-Founder, Chief Scientific Officer | ||
| Troy JD, CEO, Chairman | ||
| Antonio Gualberto, Chief Medical Officer | ||
| Marc Grasso, CFO and Chief Business Officer | ||
| Pete Spain, Executive Communications | ||
| Robert Hoffman, Independent Director | ||
| Maureen MBA, VP Management |
Kura Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kura Oncology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.23 | ||||
| Current Valuation | 1.01 B | ||||
| Shares Outstanding | 76.18 M | ||||
| Shares Owned By Insiders | 1.75 % | ||||
| Shares Owned By Institutions | 98.25 % | ||||
| Number Of Shares Shorted | 10.41 M | ||||
| Price To Earning | (9.03) X | ||||
| Price To Book | 3.73 X | ||||
| EBITDA | (164.96 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kura Oncology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Complementary Tools for Kura Stock analysis
When running Kura Oncology's price analysis, check to measure Kura Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kura Oncology is operating at the current time. Most of Kura Oncology's value examination focuses on studying past and present price action to predict the probability of Kura Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kura Oncology's price. Additionally, you may evaluate how the addition of Kura Oncology to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |
Is Kura Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. If investors know Kura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kura Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.08) | Return On Assets (0.23) | Return On Equity (0.37) |
The market value of Kura Oncology is measured differently than its book value, which is the value of Kura that is recorded on the company's balance sheet. Investors also form their own opinion of Kura Oncology's value that differs from its market value or its book value, called intrinsic value, which is Kura Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kura Oncology's market value can be influenced by many factors that don't directly affect Kura Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kura Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kura Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kura Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.